Receptor-Based Modeling and 3D-QSAR for a Quantitative Production of the Butyrylcholinesterase Inhibitors Based on Genetic Algorithm

Three-dimensional quantitative structure-activity relationship (3D-QSAR) models have been constructed using the comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) for a series of structurally related steroidal alkaloids as butyrylcholinesterase (BuChE) inhibitors. Docking studies were employed to position the inhibitors into the BuChE active site to determine the most probable binding mode. The strategy was to explore multiple inhibitor conformations in producing a more reliable 3D-QSAR model. These multiple conformations were derived using the FlexS program. The conformation selection step for CoMFA was done by genetic algorithm. The genetic algorithm based CoMFA approach was found to be the best. Both CoMFA and CoMSIA yielded significant cross-validated q(2) values of 0.701 and 0.627 and the r(2) values of 0.979 and 0.982, respectively. These statistically significant models were validated by a test set of five compounds. Comparison of CoMFA and CoMSIA contour maps helped to identify structural requirements for the inhibitors and serves as a basis for the design of the next generation of the inhibitor analogues. The results demonstrate that the combination of ligand-based and receptor-based modeling with use of a genetic algorithm is a powerful approach to build 3D-QSAR models. These data can be used for the lead optimization process with respect to inhibition enhancement which is important for the drug discovery and development for Alzheimer's disease.

[1]  N. Greig,et al.  Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. , 2001, Journal of medicinal chemistry.

[2]  N. Greig,et al.  The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics , 2000, Acta neurologica Scandinavica. Supplementum.

[3]  N. Greig,et al.  Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. , 1999, Journal of medicinal chemistry.

[4]  A Tropsha,et al.  Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. , 1996, Journal of medicinal chemistry.

[5]  P Taylor,et al.  Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. , 1993, Biochemistry.

[6]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[7]  Patrick Masson,et al.  Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. , 2005, Biochemistry.

[8]  O. Lockridge,et al.  Comparison of butyrylcholinesterase and acetylcholinesterase. , 1989, The Biochemical journal.

[9]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[10]  Gerhard Klebe,et al.  Comparative Molecular Similarity Indices Analysis: CoMSIA , 1998 .

[11]  D. Kaufer,et al.  Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity , 2002, Science.

[12]  J. Vonesch,et al.  Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo , 2002, Nature Neuroscience.

[13]  P. Taylor,et al.  Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. , 2000, The Journal of pharmacology and experimental therapeutics.

[14]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[15]  Li Wang,et al.  Hierarchy of protein assembly at the vertex ring domain for yeast vacuole docking and fusion , 2003, The Journal of cell biology.

[16]  Zaheer-ul-Haq,et al.  New pregnane-type steroidal alkaloids from Sarcococca saligna and their cholinesterase inhibitory activity , 2004, Steroids.

[17]  D. Ingram,et al.  Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. , 1995, Neuroreport.

[18]  G. Zeng,et al.  3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K. , 2006, Bioorganic & medicinal chemistry.

[19]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[20]  Prashant V Desai,et al.  Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies , 2003, Protein science : a publication of the Protein Society.

[21]  Xin Hu,et al.  Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors. , 2005, Bioorganic & medicinal chemistry.

[22]  Ricardo L. Mancera,et al.  A new quantum stochastic tunnelling optimisation method for protein–ligand docking , 2003 .

[23]  Margaret A. Johnson,et al.  A novel modeling protocol for protein receptors guided by bound-ligand conformation. , 2003, Biochemistry.

[24]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[25]  P. Masson,et al.  Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. , 2000, Neurotoxicology.

[26]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[27]  P. Masson,et al.  [Butyrylcholinesterase: 3D structure, catalytic mechanisms]. , 2005, Annales pharmaceutiques francaises.

[28]  A. Çokuğraş,et al.  Butyrylcholinesterase : Structure and Physiological Importance , 2003 .

[29]  Klaus R Liedl,et al.  Molecular docking studies of natural cholinesterase-inhibiting steroidal alkaloids from Sarcococca saligna. , 2003, Journal of medicinal chemistry.

[30]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[31]  C. Dominguez,et al.  HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.

[32]  C. Lemmen,et al.  FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.

[33]  B. L. Du,et al.  Human Cholinesterases and Anticholinesterases , 1994 .

[34]  Thy-Hou Lin,et al.  Modeling Ligand-Receptor Interaction for Some MHC Class II HLA-DR4 Peptide Mimetic Inhibitors Using Several Molecular Docking and 3D QSAR Techniques , 2005, J. Chem. Inf. Model..

[35]  Atul Purohit,et al.  Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. , 2003, Bioorganic & medicinal chemistry letters.

[36]  Hongbin Yuan,et al.  CoMFA study of piperidine analogues of cocaine at the dopamine transporter: exploring the binding mode of the 3 alpha-substituent of the piperidine ring using pharmacophore-based flexible alignment. , 2004, Journal of medicinal chemistry.

[37]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.

[38]  Somsak Tonmunphean,et al.  3D-QSAR studies on natural acetylcholinesterase inhibitors of Sarcococca saligna by comparative molecular field analysis (CoMFA). , 2003, Bioorganic & medicinal chemistry letters.

[39]  J. Kirsch,et al.  Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase. , 1986, Biochemistry.

[40]  C. Thompson,et al.  Probing the active sites of butyrylcholinesterase and cholesterol esterase with isomalathion: conserved stereoselective inactivation of serine hydrolases structurally related to acetylcholinesterase. , 2001, Chemical research in toxicology.

[41]  C. W. Ragsdale,et al.  Pseudocholinesterase staining in the primary visual pathway of the macaque monkey , 1982, Nature.

[42]  Zaheer-ul-Haq,et al.  New Cholinesterase-Inhibiting Steroidal Alkaloids from Sarcococca saligna , 2004 .

[43]  A. Debnath,et al.  Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. , 1999, Journal of medicinal chemistry.

[44]  N Butters,et al.  Clinical assessment of memory disorders in amnesia and dementia. , 1995, Annual review of psychology.

[45]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[46]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[47]  Jeremy R. H. Tame,et al.  Scoring functions: A view from the bench , 1999, J. Comput. Aided Mol. Des..

[48]  Atta-ur-rahman,et al.  Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. , 2001, Journal of natural products.

[49]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[50]  J. Sussman,et al.  Structure and functions of acetylcholinesterase and butyrylcholinesterase. , 1993, Progress in brain research.

[51]  S Forrest,et al.  Genetic algorithms , 1996, CSUR.

[52]  A. Robitzki,et al.  The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′butyrylcholinesterase-DNA study , 2000, Progress in Neurobiology.

[53]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[54]  P A Kollman,et al.  Calculation and prediction of binding free energies for the matrix metalloproteinases. , 2000, Journal of medicinal chemistry.

[55]  J L Sussman,et al.  Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  José L. Medina-Franco,et al.  Docking-based CoMFA and CoMSIA studies of non-nucleoside reverse transcriptase inhibitors of the pyridinone derivative type , 2004, J. Comput. Aided Mol. Des..

[57]  M. Mesulam,et al.  Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.

[58]  Zaheer-ul-Haq,et al.  Cholinesterase inhibitory and spasmolytic potential of steroidal alkaloids , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[59]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[60]  B. P. Doctor,et al.  Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. , 1997, Biochemistry.

[61]  Hongbin Yuan,et al.  Improved 3D-QSAR CoMFA of the dopamine transporter blockers with multiple conformations using the genetic algorithm. , 2006, Bioorganic & medicinal chemistry letters.

[62]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[63]  Zaheer-ul-Haq,et al.  Pregnane-type steroidal alkaloids of Sarcococca saligna: a new class of cholinesterase inhibitors , 2002 .

[64]  J. Buccafusco,et al.  The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development , 2003, Journal of Pharmacology and Experimental Therapeutics.

[65]  Bernard R Brooks,et al.  A core-weighted fitting method for docking atomic structures into low-resolution maps: application to cryo-electron microscopy. , 2003, Journal of structural biology.

[66]  F. Vallette,et al.  Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.

[67]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[68]  Zaheer-ul-Haq,et al.  Kinetics and structure-activity relationship studies on pregnane-type steroidal alkaloids that inhibit cholinesterases. , 2004, Bioorganic & medicinal chemistry.

[69]  Gyanendra Pandey,et al.  CoMFA and Docking Studies on Glycogen Phosphorylase a Inhibitors as Antidiabetic Agents , 2005, J. Chem. Inf. Model..

[70]  Jared Spidel,et al.  Kinetic and docking studies of the interaction of quinones with the quinone reductase active site. , 2003, Biochemistry.

[71]  P. Masson,et al.  The reactant state for substrate-activated turnover of acetylthiocholine by butyrylcholinesterase is a tetrahedral intermediate. , 2005, Journal of the American Chemical Society.

[72]  Zaheer-ul-Haq,et al.  New Steroidal Alkaloids From Sarcococca Saligna , 2003, Natural product research.

[73]  A. Smith,et al.  Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. , 1997, Human molecular genetics.

[74]  P. Taylor,et al.  Acetylcholinesterase inhibition by fasciculin: Crystal structure of the complex , 1995, Cell.